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Cardiovascular Complications of Cancer Therapy
Incidence, Pathogenesis, Diagnosis, and Management
Edward T. H. Yeh, MD,*‡ Courtney L. Bickford, PHARMD, BCPS†
Houston, Texas
Cancer treatment today employs a combination of chemotherapy, radiotherapy, and surgery to prolong life and
provide cure. However, many of these treatments can cause cardiovascular complications such as heart failure,
myocardial ischemia/infarction, hypertension, thromboembolism, and arrhythmias. In this article we review the
incidence of cardiotoxicity caused by commonly used chemotherapeutic agents as well as discuss the pathogen-
esis, diagnosis, management, and prevention of these cardiovascular side effects. Cardiotoxicity related to anti-
cancer treatment is important to recognize as it may have a significant impact on the overall prognosis and sur-
vival of cancer patients, and it is likely to remain a significant challenge for both cardiologists and oncologists in
the future due to an increasing aging population of patients with cancer and the introduction of many new cancer
therapies. (J Am Coll Cardiol 2009;53:2231–47) © 2009 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.02.050n
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hntineoplastic therapy is frequently complicated by the
evelopment of cardiotoxicity. This subject is of rising
oncern for both cardiologists and oncologists since many
f these adverse effects are likely to have significant
onsequences on patient outcomes. Therefore, identify-
ng and understanding these effects is crucial to the
uccessful management of cancer patients with cardiovas-
ular complications.
The purpose of this review is to attempt to summarize the
urrent state of knowledge of common cardiovascular com-
lications, such as heart failure (HF), myocardial ischemia,
ypertension (HTN), thromboembolism, QT prolongation,
nd bradycardia associated with frequently used anticancer
edications at the University of Texas M. D. Anderson
ancer Center (MDACC). A MEDLINE search for each
f the aforementioned cardiovascular side effects and asso-
iated chemotherapeutic agents was performed. The most
ecent review articles and key research papers establishing
he chemotherapy’s incidence, diagnosis, pathophysiology,
nd management of its cardiovascular complications were
ncluded. For anticancer therapies in which the incidence of
particular cardiotoxicity was considered rare, or when
here were only case reports available, these agents were
xcluded from this review. During the literature search
onducted for this report, we found that in many cases
rimary literature was lacking in regard to the rate of these
ide effects reported in the package insert, particularly for
rom the *Department of Cardiology and the †Division of Pharmacy, University of
exas M. D. Anderson Cancer Center, Houston, Texas; and the ‡Texas Heart
nstitute/St. Luke’s Episcopal Hospital, Houston, Texas. Dr. Yeh is a consultant for
elgene and is the McNair Scholar of the Texas Heart Institute.c
Manuscript received August 7, 2008; revised manuscript received January 27, 2009,
ccepted February 6, 2009.ewer targeted therapies. In these instances, the package
nsert was the only published information available to report
he incidence of cardiotoxicity. In addition, scientific ab-
tracts presented at national conferences, the Food and
rug Administration (FDA) website, as well as the exten-
ive clinical experience of the Department of Cardiology at
DACC were utilized to comprise this review. The re-
orted rates of cardiotoxicity were obtained from available
ublished literature and they apply to the follow-up periods
or each agent, which were variable. Therefore, in this
eport, incidence should be understood as the number of
ew cases of cardiotoxicity described over the variable
ollow-up period studied.
For every cardiotoxic side effect discussed, a table was
reated. In each of the tables presented, the incidence of the
ardiotoxic side effect being discussed is listed. In addition,
he frequency of use for each chemotherapeutic agent in the
ast year (January 1, 2007 to December 31, 2007) at
DACC is represented. If 5,000 doses per year were
ispensed, then the agent was assigned ; if 1,000 to
,000 doses per year were dispensed, the agent was assigned
; lastly, if1,000 doses were dispensed per year, then
as assigned to correspond to its frequency of use.
F
everal therapies for cancer have been associated with the
evelopment of left ventricular dysfunction (LVD) and/or
F. The cumulative dose, the administration schedule, and
he concomitant use of other cardiotoxic therapies deter-
ine the likelihood of cardiomyopathy (CMP). Table 1
ighlights the incidences of LVD associated with selected
hemotherapeutic agents.
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Chemotherapy and Cardiotoxicity June 16, 2009:2231–47Incidence. ANTHRACYCLINES. An-
thracycline-induced cardiotoxic-
ity has been categorized into
acute, early-onset chronic pro-
gressive, and late-onset chronic
progressive (1,2). Acute cardio-
toxicity occurs in 1% of pa-
tients immediately after infusion
of the anthracycline and mani-
fests as an acute, transient de-
cline in myocardial contractility,
which is usually reversible (3).
The early-onset chronic progres-
sive form occurs in 1.6% to 2.1%
of patients, during therapy or
within the first year after treat-
ment (3). Late-onset chronic
progressive anthracycline-induced
cardiotoxicity occurs at least 1
year after completion of therapy
in 1.6% to 5% of patients (3).
Early- and late-onset chronic
progressive cardiotoxicity typi-
cally presents as dilated CMP in
adults, which can be progressive
(2). Late-occurring cardiotoxic-
ity may not become clinically ev-
ident until 10 to 20 years after
the first dose of cancer treatment.
In addition, the Childhood Can-
cer Survivor study demonstrated
that 30 years after therapy, 73%
of pediatric cancer survivors will
develop at least 1 chronic physi-
cal health condition and 42% a
severe, life-threatening or dis-
bling condition, or die of a chronic condition (4). The risk
f clinical cardiotoxicity increases with a cumulative dose of
nthracycline. Studies that have looked at the cumulative
robability of doxorubicin-induced HF have found that it
ccurs in 3% to 5% with 400 mg/m2, 7% to 26% at 550
g/m2, and 18% to 48% at 700 mg/m2 (3,5,6). However, in
retrospective review of 3 trials, the incidence of HF was
ound to be 26% with cumulative doses of 550 mg/m2 (7).
or this reason, the maximum lifetime cumulative dose for
oxorubicin is 400 to 550 mg/m2 (3). However, epirubicin
r idarubicin appears to have less incidence of HF (8–10).
isk factors for anthracycline toxicity include cumulative
ose; intravenous bolus administration; higher single doses;
istory of prior irradiation; the use of other concomitant
gents known to have cardiotoxic effects such as cyclophos-
hamide, trastuzumab, and paclitaxel; female gender; un-
erlying cardiovascular disease; age (young and old age); and
ncreased length of time since anthracycline completion
Abbreviations
and Acronyms
ACE  angiotensin-
converting enzyme
ACS  acute coronary
syndrome
ATE  arterial thrombotic
event
ATP  adenosine
triphosphate
CMP  cardiomyopathy
CTCL  cutaneous T-cell
lymphoma
DVT  deep vein
thrombosis
FDA  Food and Drug
Administration
HF  heart failure
HTN  hypertension
LMWH  low-molecular-
weight heparin
LVD  left ventricular
dysfunction
LVEF  left ventricular
ejection fraction
MI  myocardial infarction
MUGA  multigated
acquisition scan
PE  pulmonary embolism
VEGF  vascular
endothelial growth factor
VTE  venous
thromboembolism
5-FU  5-fluorouracil1,2,7). (LKYLATING AGENTS. Cyclophosphamide. HF has been asso-
iated with cyclophosphamide therapy in 7% to 28% of
atients (8,11–13). Clinical manifestations of cardiotoxicity
ange from asymptomatic pericardial effusions to HF and
yopericarditis (11,13). The risk of cardiotoxicity appears
o be dose related (150 mg/kg and 1.5 g/m2/day) and
ccurs within 1 to 10 days after the administration of the
rst dose of cyclophosphamide (8). Besides total dose, risk
actors for cardiotoxicity include prior anthracycline or
itoxantrone therapy and mediastinal radiation (8,12).
fosfamide. In a retrospective review of patients treated with
fosfamide combination chemotherapy, cardiotoxicity devel-
ped in 17% of patients (8,14). Acute onset of HF occurred
ithin 6 to 23 days after the first dose of ifosfamide, and a
ose-response trend was observed (doses 12.5 g/m2) (8).
NTIMETABOLITES. Clofarabine. According to the package
nsert, LVD was noted in 27% of pediatric acute lympho-
lastic leukemia patients. In most cases, LVD appeared to
e transient (10).
NTIMICROTUBULE AGENTS. Docetaxel. The incidence of
F associated with docetaxel ranges from 2.3% to 8%
hemotherapy Associatedith Left Ventricular Dysfunction
Table 1 Chemotherapy AssociatedWith Left Ventricular Dysfunction
Chemotherapy Agents Incidence (%)
Frequency
of Use
Anthracyclines
Doxorubicin (Adriamycin) (6,7) 3–26* 
Epirubicin (Ellence) (10) 0.9–3.3 
Idarubicin (Idamycin PFS) (8) 5–18 
Alkylating agents
Cyclophosphamide (Cytoxan) (8,11–13) 7–28 
Ifosfamide (Ifex) (8,14) 17 
Antimetabolites
Clofarabine (Clolar) (10) 27 
Antimicrotubule agents
Docetaxel (Taxotere) (10,15,16) 2.3–8 
Monoclonal antibody-based tyrosine
kinase inhibitors
Bevacizumab (Avastin) (10,18,19) 1.7–3 
Trastuzumab (Herceptin) (20–28) 2–28 
Proteasome inhibitor
Bortezomib (Velcade) (10,17) 2–5 
Small molecule tyrosine kinase inhibitors
Dasatinib (Sprycel) (10) 2–4 
Imatinib mesylate (Gleevec) (34,35) 0.5–1.7 
Lapatinib (Tykerb) (32) 1.5–2.2 
Sunitinib (Sutent) (36,37) 2.7–11 
f 5,000 doses per year were dispensed, then the agent was assigned ; if 1,000 to 5,000
oses per year were dispensed, the agent was assigned; lastly, if 1,000 doses were dispensed
er year, then was assigned to correspond to its frequency of use. *At a cumulative dose of 550
g/m2. Medication manufacturers (and locations): Adriamycin, Pharmacia & Upjohn SpA, Milano,
taly; Ellence, Idamycin, and Sutent, Pfizer Inc., New York, New York; Cytoxan, Ifex, and Sprycel,
ristol-Myers Squibb, Princeton, New Jersey; Clolar, Genzyme Oncology, Cambridge, Massachu-
etts; Taxotere, Sanofi-Aventis U.S. LLC, Bridgewater, New Jersey; Avastin and Herceptin, Genen-
ech Inc., South San Francisco, California; Velcade, Millenium Pharmaceuticals, Cambridge,
assachusetts; Gleevac, Novartis Pharmaceuticals Corp., East Hanover, New Jersey; Tykerb,
laxoSmithKline, Research Triangle Park, North Carolina.10,15,16). In a trial comparing docetaxel plus doxoru-
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June 16, 2009:2231–47 Chemotherapy and Cardiotoxicityicin and cyclophosphamide (TAC) with fluorouracil
lus doxorubicin and cyclophosphamide (FAC) in 1,491
reast cancer patients, the overall incidence of HF at 55
onths was 1.6% in the TAC group versus 0.7% in the
AC group (15). At 70 months’ follow-up, HF was
eported in 2.3% of the docetaxel arm compared with
.9% of the control arm (10). However, the incidence of
ocetaxel-induced HF was higher (8%) in another breast
ancer trial (16).
ROTEASOME INHIBITOR. Bortezomib. In a pivotal clinical
rial, 669 multiple myeloma patients were treated with
ortezomib or high-dose dexamethasone (17). The inci-
ence of cardiac disorders during treatment with bort-
zomib was 15% versus 13% in those patients treated with
examethasone. HF events occurred in 5% of bortezomib-
reated patients and in 4% of dexamethasone-treated patients.
wo percent of patients in each of the treatment groups
eveloped HF (10,17).
NTIBODY-BASED TYROSINE KINASE INHIBITORS. Bevaci-
umab. The incidence of HF ranges from 1.7% to 3%. Per
he prescribing information, HF developed in 24 of 1,459
atients (1.7%) treated with bevacizumab during clinical
rials (10). In 2 phase III clinical studies in metastatic breast
ancer patients, the rate of grade 3 to 4 HF or CMP in the
evacizumab-treated arms was 2.2% to 3% (18,19).
rastuzumab. The overall incidence of trastuzumab varies
n the literature from 2% to 28%. The incidence of cardiac
ysfunction ranges from 2% to 7% when trastuzumab is
sed as monotherapy, 2% to 13% when trastuzumab is used
n combination with paclitaxel, and up to 27% when
rastuzumab is used concurrently with anthracyclines plus
yclophosphamide (20–27). In a recent study looking at the
ong-term cardiac tolerability of trastuzumab at MDACC,
he overall incidence of cardiotoxicity was 28% (28). Cited
isk factors for trastuzumab-induced CMP include age 50
ears, borderline left ventricular ejection fraction (LVEF)
efore treatment, history of cardiovascular disease, the
equence in which chemotherapy is administered, and prior
reatment with anthracyclines (cumulative doses 300
g/m2) (20,26,28–31).
MALLMOLECULETYROSINEKINASE INHIBITORS. Dasatinib. The
ncidence of HF reported with dasatinib therapy ranges
rom 2% to 4%. In patients with leukemia across all
asatinib studies (n 2,182), HF or cardiac dysfunction (all
rades) occurred in 2%, with grade 3 or 4 occurring in 1% of
hese patients (10). During the phase III dose-optimization
tudy, HF or LVD was reported in up to 4% of chronic phase
hronic myeloid leukemia patients receiving dasatinib. Grade 3
r 4 HF/LVD occurred in up to 2% of patients (10).
apatinib. The cardiac safety of lapatinib was recently
valuated in a pooled analysis of 3,689 patients enrolled in
hase I to III lapatinib clinical trials (32). Cardiac events
ere defined as symptomatic (grade 3 or 4 LVD) orsymptomatic (LVEF decreases 20% relative to baseline and below the institution’s lower limit of normal; no
ymptoms). Of the 3,689 patients, 60 (1.6%) experienced a
ardiac event. Asymptomatic cardiac events were reported in
3 patients (1.4%), and symptomatic events occurred in 7
0.2%). In patients treated with prior anthracyclines, tras-
uzumab, or neither, the incidence of cardiac events was
.2%, 1.7%, and 1.5%, respectively. The mean time to onset
f cardiac events was 13 weeks (32).
matinib mesylate. The exact incidence of cardiotoxicity
ssociated with imatinib is unknown. The idea that imatinib
auses cardiotoxicity was first introduced by Kerkela et al.
33) when they reported 10 patients who developed severe
F while on imatinib therapy. In addition, they showed
hat imatinib-treated mice develop left ventricular contrac-
ile dysfunction and cellular abnormalities suggestive of
oxic myopathy (33). In correspondence to this report,
ovartis conducted a retrospective review of their clinical
atabase containing 6 registration trials of 2,327 patients
reated with imatinib monotherapy. The incidence of HF
as 0.5% (34). Similarly, among 1,276 patients treated with
matinib during clinical trials at MDACC, 22 patients
1.7%) developed HF (35).
unitinib. Early clinical trials involving patients with gas-
rointestinal stromal tumor and metastatic renal cell cancer
eported LVD in 4% to 11% of patients (36). Recently, 2
etrospective reviews have been published examining the
ardiotoxicity of sunitinib (36,37). Chu et al. (37) retrospec-
ively reviewed all cardiovascular events in 75 imatinib-
esistant metastatic gastrointestinal stromal tumor patients.
leven percent of patients had a cardiac event, with New
ork Heart Association functional class III to IV HF
ecorded in 8% of patients. In another retrospective review,
of 224 (2.7%) sunitinib-treated patients developed HF
36). The only significant risk factor associated with the
evelopment of HF was coronary artery disease (37). The
ean time to development of HF was variable, 22 days to
7 weeks (36,37). Sunitinib-induced HF appears to respond
ell to medical therapy; however, CMP may not be com-
letely reversible (36).
athophysiology. Anthracyclines. There are several hy-
otheses to explain the mechanism of anthracycline-induced
ardiotoxicity, but free radical formation is generally ac-
epted as the main mechanism. Other mechanisms have
lso been postulated including apoptosis; transcriptional
hanges in intracellular adenosine triphosphate (ATP) pro-
uction in cardiac myocytes; down-regulation of messenger
ibonucleic acid expression for sarcoplasmic reticulum
alcium-ATPase, which decreases cardiac contractility; pro-
onged drug-related depression in cardiac glutathione per-
xidase activity; and respiratory defects associated with
itochondrial deoxyribonucleic acid damage (3). However,
t has recently been proposed that doxorubicin may cause
ardiotoxicity through its interference with topoisomerase II
eta (38).
yclophosphamide. The precise mechanism of cyclophosph-
mide cardiotoxicity is unknown. It is hypothesized that
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Chemotherapy and Cardiotoxicity June 16, 2009:2231–47yclophosphamide causes direct endothelial injury, followed
y extravasation of toxic metabolites resulting in damage
o cardiomyocytes, interstitial hemorrhage, and edema
8,12,13,39). Intracapillary microemboli may develop as
ell, resulting in ischemic myocardial damage (13,39).
yocardial ischemia caused from coronary vasospasm is
nother proposed mechanism of cardiotoxicity (8).
fosfamide. Given that ifosfamide and cyclophosphamide
re structurally similar, it is possible that ifosfamide may
nduce HF through a similar mechanism. However, no
istopathological evidence of hemorrhagic myocarditis,
hich is the hallmark of cyclophosphamide toxicity, was
ound in ifosfamide-treated patients (14). It has also been
roposed that since ifosfamide causes nephrotoxicity, the
ecrease in glomerular filtration rate may delay elimination of
ardiotoxic metabolites. In addition, fluid disturbances, acid-
ase, and electrolyte disturbances related to tubular defects may
e factors contributing to cardiac disturbances (14).
evacizumab. The mechanism of HF associated with bev-
cizumab may be related to uncontrolled HTN and inhibi-
ion of vascular endothelial growth factor (VEGF)/VEGF
eceptor signaling (40). Animal studies have demonstrated
hat angiogenesis plays a key role in the normal adaptive
esponse to a pressure load. Studies that have utilized
trategies mimicking the mechanism of bevacizumab have
hown that pressure overload resulted in reduction of
yocardial capillary density, global contractile dysfunction,
ardiac fibrosis, and eventually decompensated HF (40).
rastuzumab and lapatinib. Cardiotoxicity caused by tras-
uzumab is most likely secondary to inhibition of cardiomy-
cyte human epidermal growth factor receptor 2, also
nown as ErbB2 signaling, thereby interfering with normal
rowth, repair, and survival of cardiomyocytes (22,41,42).
y binding to ErbB2, it may regulate mitochondrial integ-
ity through the BCL-X proteins, leading to ATP depletion
nd contractile dysfunction (43). In a study by Sawyer et al.
44), the addition of an antibody to ErbB2 in mice exposed
o anthracyclines caused increasing myofibrillar disarray,
hich may explain the contractile dysfunction seen in
atients treated with concurrent trastuzumab and anthracy-
lines. Other mechanisms include drug–drug interactions
nd immune-mediated destruction of cardiomyocytes (45).
here may also be a mechanism of cardiotoxicity indepen-
ent of ErbB2 signaling, since both lapatinib and trastu-
umab inhibit ErbB2, but trastuzumab is associated with a
igher incidence of HF (30).
ortezomib. The mechanism of HF associated with bort-
zomib is unknown, but it has been proposed that it may
ause cardiotoxicity through proteasome inhibition (46). In
hronic CMP, it is thought that the ubiquitin–proteasome
ystem may be activated, and that this may be an adaptive
echanism for maintaining a normal stroke volume. In
ddition, susceptibility to cardiovascular disease has been
ttributed to an age-related decrease in proteasome activity.
herefore, in patients who possess a baseline presence ofubclinical CMP, the ubiquitin–proteasome system is acti- dated, and this may predispose them to bortezomib cardio-
oxicity (46).
asatinib. The mechanism of dasatinib-induced cardiotox-
city may be similar to imatinib since they are both inhibi-
ors of Abl. Besides Abl, dasatinib also inhibits Src and a
umber of other kinases, which may be involved in the
evelopment of cardiotoxicity as well (40).
matinib. Imatinib may induce cardiotoxicity through inhi-
ition of c-Abl (33,43). Cultured cardiomyocytes with an
matinib-resistant mutant of c-Abl are largely protected
rom imatinib cardiotoxicity, suggesting that c-Abl has a
reviously unrecognized survival function in cardiomyocytes
33). A recent study by Fernandez et al. (47) demonstrated
hat a redesign of imatinib appears to reduce its cardiotoxic
ffects.
unitinib. Animal studies have shown that sunitinib in-
uces mitochondrial damage in cardiomyocytes, but no
poptosis (37). Khakoo et al. (36) hypothesize that HTN
ay also play an important role, since sunitinib may inhibit
receptor tyrosine kinase that helps to regulate the response
f cardiomyocytes in the setting of hypertensive stress.
astly, Force et al. (43) suggest that sunitinib may cause
ardiotoxicity through inhibition of ribosomal S6 kinase,
eading to the activation of the intrinsic apoptotic pathway
nd ATP depletion.
iagnosis. HF is a clinical diagnosis, which combines a
horough clinical history of the patient and physical exam-
nation combined with diagnostic tests such as electrocar-
iogram, chest radiography, and laboratory tests. According
o the American College of Cardiology/American Heart
ssociation guidelines, a panel of routine blood tests should
e obtained, and noninvasive imaging (e.g., contrast echo-
ardiography, multigated acquisition scan [MUGA]) should
e used in conjunction to evaluate cardiac function.
onitoring. To detect cardiac dysfunction in patients who
re treated with chemotherapy, regular monitoring of the
eart function during treatment is important. A baseline
valuation of LVEF needs to be obtained for comparison,
nd it is recommended that the same methodology be used
or comparing serial studies. Serial assessment of LVEF was
rst shown to be useful in clinical practice by Alexander
t al. (49). Based on their experiences, algorithms have
een developed for serial monitoring of LVEF during
nthracycline-based therapy (50,51). Measuring systolic
unction through evaluation of the LVEF with either MUGA
r echocardiography is one of the most commonly used
easurements in monitoring and diagnosing chemotherapy-
nduced CMP; however, it is not sensitive for early detection of
re-clinical cardiac disease (subclinical), and it is influenced by
ontractility and pre-load/afterload effects leading to transient
hanges. Therefore, other measurements of systolic function
e.g., fraction shortening) and diastolic function (e.g., E/A
atio) have been used to detect early cardiotoxicity in addition
o LVEF (52).
Endomyocardial biopsy remains the gold standard for
iagnosis since it is the most sensitive and specific; however,
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June 16, 2009:2231–47 Chemotherapy and Cardiotoxicityhe invasiveness of the procedure limits its use. MUGA
cans are noninvasive, which make them an attractive option
or routine clinical monitoring; however, MUGA scans
rimarily detect drops in LVEF, but no other information
an be obtained. In addition, it is insensitive for detecting
arly toxicity. In contrast, echocardiography, which is also
oninvasive, can identify both systolic and diastolic dysfunc-
ion, as well as valvular and pericardial disease (52).
Biochemical markers may also indicate myocardial injury
efore the changes in LVEF are apparent. Troponin, as a
iomarker of cardiotoxicity associated with chemotherapy,
as been investigated, but the utility of troponin testing
epends on a prospective definition of a cutoff with good
pecificity for clinically significant HF. In 1 study, the
levation of troponin I soon after high-dose chemotherapy
redicted the future development of LVEF depression (53),
nd in another study, troponin I elevations identified
atients at different risks of future cardiac events (54).
-type natriuretic peptide has also been shown to be
ositively correlated with cardiac events and subclinical
ardiotoxicity, particularly with evidence to suggest it cor-
elates more to diastolic as opposed to systolic dysfunction
55–57).
revention. Since one of the most significant risk factors
or anthracycline-induced CMP is the cumulative dose the
atient has received, one of the most significant preventative
easures is to minimize the patient’s lifetime cumulative
ose (3). Other preventative measures that have been shown
o decrease cardiotoxicity associated with anthracyclines
nclude altering the anthracycline administration (e.g., con-
inuous infusion vs. bolus administration), use of anthracy-
line analogues (e.g., idarubicin, epirubicin, mitoxantrone)
r liposomal anthracyclines, and the addition of cardiopro-
ectants (e.g., dexrazoxane) to anthracycline treatment (3).
reatment. Currently, there are no HF guidelines devel-
ped specifically for cancer patients. Until then, the guide-
ines published by the American College of Cardiology/
merican Heart Association and Heart Failure Society of
merica should be followed. Medical management of pa-
ients with stage A disease should focus on risk-factor
eduction by controlling HTN, diabetes, and hyperlipid-
mia, with the goal of preventing remodeling. Treatment of
tage B, C, and D aims at improving survival, slowing
isease progression, and alleviating symptoms. All patients
hould be on a combination of an angiotensin-converting
nzyme (ACE) inhibitors or an angiotensin II receptor
locker and a beta-blocker unless contraindicated. These
edications have been shown to reverse remodeling thereby
mproving survival. Patients with advanced HF usually
equire additional measures such as diuretics, digoxin, or
ldosterone antagonists. Patients with end-stage HF with
efractory symptoms at rest despite maximal medical ther-
py and without evidence of cancer recurrence could be
onsidered for synchronized pacing, ventricular assist de-
ice, or cardiac transplantation (48). Patients with
nthracycline-induced cardiotoxicity may show clinical im- crovement in response to treatment, but because myocyte
eath is characteristic of this entity, resolution of the
nderlying process does not usually occur (22).
There is some evidence supporting the use of ACE
nhibitors in patients with anthracycline-induced CMP
58–60). In cancer patients undergoing high-dose chemo-
herapy, enalapril was shown to prevent a decline in LVEF
s well as cardiac events when compared with the control
roup (58). Although ACE inhibitors may be beneficial
ompared with placebo, they do not prevent progressive
ardiac dysfunction in all patients. In an observational study
f 18 children treated with enalapril for LVD or HF, the
eneficial effects of enalapril diminished after 6 to 10 years
ue to progressive left ventricular wall thinning (59). In
nother study of pediatric cancer survivors with subclinical
ardiac dysfunction, enalapril reduced left ventricular end-
ystolic wall stress, but this was not associated with an
mprovement in exercise capacity, contractile state, or ejec-
ion fraction compared with that seen with placebo (60).
The relationship between acute toxicity and the subse-
uent development of early and late cardiotoxicity is unclear.
n a small randomized trial, the angiotensin II receptor
locker, valsartan, blocked all of the acute effects of anthra-
ycline treatment (61). Additional clinical trials are required
o determine if blocking acute toxicity decreases the risk of
ubsequently developing early or late cardiotoxicity.
To date, there have been 4 case series that have evaluated
he benefit of beta-blockers in the treatment of anthracycline-
nduced CMP (62–65). Of the beta-blockers, carvedilol
ay have therapeutic advantages over the others in
nthracycline-induced CMP since it has been shown to
ossess antioxidant properties (66). Moreover, in a recent
linical trial, the use of carvedilol prophylactically protected
ystolic and diastolic function compared with placebo in
atients treated with anthracycline chemotherapy (67).
Discontinuation of trastuzumab is generally recom-
ended when clinically significant HF occurs. However,
atients who experience cardiotoxicity while receiving tras-
uzumab generally recover their cardiac function when
rastuzumab is discontinued over a mean time period of 1.5
onths (68). Patients who have experienced benefit with
rastuzumab therapy and who have improved cardiac func-
ion while on a standard heart regimen may restart trastu-
umab therapy while on protective HF medications and
lose cardiac monitoring (68). In addition, Memorial-
loan-Kettering Cancer Center has proposed guidelines for
he management of patients treated with trastuzumab based
n physical status and LVEF (69).
schemia
hest pain is a common cardiac event experienced by cancer
atients, often necessitating a work-up for myocardial isch-
mia. Several forms of cancer treatment (e.g., radiation,
hemotherapy) are associated with an increased risk of
oronary artery disease and/or acute coronary syndrome
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Chemotherapy and Cardiotoxicity June 16, 2009:2231–47ACS). Chemotherapeutic agents implicated in the devel-
pment of myocardial ischemia/infarction are highlighted in
able 2.
ncidence. ANTIMETABOLITES. Fluorouracil. The most
ommon symptom associated with 5-fluorouracil (5-FU)
ardiotoxicity is angina-like chest pain. In rare cases,
yocardial infarction (MI), arrhythmias, HF, cardio-
enic shock, and sudden death have been reported
70,71). The incidence of cardiotoxicity associated with
-FU varies in the literature ranging anywhere from 1%
o 68% (8,70 –79). Cardiac events tend to occur within 2
o 5 days of starting therapy, lasting up to 48 h (70).
schemic electrocardiogram (ECG) changes have been
eported in 68% of patients, but only 43% have elevations
n serum cardiac markers (80). The overall mortality has
een estimated to be 2.2% to 13% (73,76,78). Risk factors
ave not firmly been established, but high doses (800
g/m2) and continuous infusions of 5-FU have been
ssociated with higher rates of cardiotoxicity (7.6%) as
ompared with bolus injections (2%) (70,73,80). Other
ommonly cited risk factors include history of cardiovas-
ular disease, prior mediastinal radiation, and the con-
urrent use of chemotherapy (71–75,77,78,81,82).
apecitabine. The incidence and risk factors of cardiotoxic-
ty associated with capecitabine remain poorly defined.
urrently, the majority of the literature citing the incidence
f capecitabine-induced myocardial ischemia/infarction ex-
sts only as case reports or retrospective reviews. One
rospective review in 644 patients found the incidence of
apecitabine-associated cardiotoxicity to be 5.5% (74). From
he 4 retrospective reviews published, the incidence of
ardiotoxicity ranges from 3% to 9% (71,83–85). In the case
eports reviewed, the dosages of capecitabine ranged from
,500 to 2,500 mg/m2/day, and typical angina symptoms
ppeared 3 h to 4 days after therapy (72,79,80,82,86–89).
hemotherapy Associated With Ischemia
Table 2 Chemotherapy Associated With Ischemia
Chemotherapy Agents Incidence (%)
Frequency
of Use
Antimetabolites
Capecitabine (Xeloda) (71,74,83–85) 3–9 
Fluorouracil (Adrucil) (8,70,71,73–79) 1–68* 
Antimicrotubule agents
Paclitaxel (Taxol) (90,91) 1–5 
Docetaxel (Taxotere) (10,92) 1.7 
Monoclonal antibody-based tyrosine kinase
inhibitor
Bevacizumab (Avastin) (10,93,94) 0.6–1.5 
Small molecule tyrosine kinase inhibitors
Erlotinib (Tarceva) (10) 2.3 
Sorafenib (Nexavar) (10,96) 2.7–3 
or an explanation of the symbols, please see Table 1. *The incidence of ischemia varies widely
n the literature for 5-fluorouracil due to the differences in study design, definition of ischemia, and
umbers of patients. Medication manufacturers and locations: Xeloda, Roche Laboratories Inc.,
utley, New Jersey; Adrucil, Sicor Pharmaceuticals, Irvine, California; Taxol, Bristol-Myers Squibb,
rinceton, New Jersey; Tarceva, OSI Pharmaceuticals Inc., Melville, New York; Nexavar, Bayer
ealthCare Pharmaceuticals, Inc., Wayne, New Jersey; see Table 1 for others.CG changes such as ST-segment elevation were noted in bany cases (72,79,80,82,86,89) and when serum cardiac
arkers were checked, they were normal (72,80,86,89)
xcept in 1 case (79). Echocardiography (72,80,82,87–89)
nd coronary angiogram were normal (72,80,82,86,87).
revious cardiac disease was not a consistent risk factor
ince it was not present in some cases (72,80,88), but
resent in others (79,82,83,89). Lastly, a history of 5-FU
ardiotoxicity may be considered a risk factor for such effects
elated to capecitabine therapy (84,86).
NTIMICROTUBULE AGENTS. Paclitaxel. Cases of myocardial
schemia and infarction associated with paclitaxel adminis-
ration have been described. Rowinsky et al. (90) reviewed
he cardiac events in 4 clinical trials, and reported that
anifestations of cardiac ischemia were observed in 5% of
atients. In 198 patients treated with paclitaxel for ovarian
ancer, 0.5% experienced a MI (91). Lastly, in a review of
he Cancer Therapy Evaluation Program’s Adverse Drug
eaction database, which followed treatment of more than
,400 patients, the overall incidence of grade 4 and 5 cardiac
vents was 0.29% (91). These events occurred during and up
o 14 days after paclitaxel administration (91). Most of the
ases reported that patients had known cardiac risk factors
ncluding HTN and coronary artery disease.
ocetaxel. In the package insert, the incidence of myocar-
ial ischemia associated with docetaxel is 1.7% (10). This
ncidence comes from a clinical trial conducted by Ver-
orken et al. (92), which randomized 355 patients with
noperable, locally advanced squamous cell carcinoma of the
ead and neck to receive a standard regimen of cisplatin and
-FU or the same regimen plus docetaxel. Myocardial
schemia was reported in 1.7% of the docetaxel arm com-
ared with 0.6% of the control arm (10,92). The authors did
ot publish this side effect in the clinical trial; therefore, the
nly information available for myocardial ischemia was
ound in the package insert.
ONOCLONAL ANTIBODY-BASED TYROSINE KINASE INHIBI-
ORS. Bevacizumab. Arterial thrombotic events (ATEs)
end to occur more frequently in patients treated with
evacizumab with chemotherapy as compared with patients
reated with chemotherapy alone (10). In a pooled analysis
f 1,745 patients from 5 randomized controlled trials in
etastatic colorectal, nonsmall cell lung cancer, and meta-
tatic breast cancer patients, the overall incidence of ATEs
as 3.8% (93). When looking at MI/angina specifically, the
ncidence was 1.5% versus 1% in the bevacizumab group as
ompared with the control group, respectively (93). In an
ngoing observational study of 1,953 patients receiving
evacizumab plus chemotherapy, the incidence of serious
TEs was 1.8%. Of the patients identified with an ATE, 11
atients had a MI (0.6%) (94). Bevacizumab-associated
TEs were reported to occur at any time during therapy,
lthough in both studies mentioned, the median time to
vent was approximately 3 months. Events did not seem to
e associated with dose or cumulative exposure. Age 65
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June 16, 2009:2231–47 Chemotherapy and Cardiotoxicityears (93) and a history of prior ATEs were identified as risk
actors (93,94).
MALL MOLECULE TYROSINE KINASE INHIBITORS. Erlotinib. MI/
schemia was reported in 2.3% of patients who received
rlotinib 100 mg/day with gemcitabine, compared with that
een in 1.2% of patients who received gemcitabine alone, for
he treatment of pancreatic cancer (10). The manufacturer
btained these results in a trial conducted by Moore et al. (95);
owever, the incidence of thromboembolism was not
ublished.
orafenib. Approximately 3% of patients in clinical trials
ave experienced myocardial ischemia with sorafenib. In an
npublished clinical trial, MI/ischemia occurred among
.7% of hepatocellular cancer patients treated with sorafenib
ompared with 1.3% of patients in the placebo group (10).
imilarly, sorafenib was associated with a higher incidence
f MI/ischemia compared with placebo among patients
reated for renal cell carcinoma (3% vs. 1%) (96).
athophysiology. FLUOROURACIL AND CAPECITABINE. The
athogenesis of cardiotoxicity associated with 5-FU and
apecitabine is unknown. Coronary artery thrombosis, ar-
eritis, or vasospasm has been proposed as the most likely
nderlying mechanisms (74). However, the failure of er-
onovine and 5-FU to elicit vasospasm during cardiac
atheterizations, in addition to the variable efficacy of
oronary vasodilating medications weakens the idea of
-FU–induced vasospasm (74,81,86,97). In 1 study, in-
reased endothelin-1 levels were found in some patients,
upporting the theory of coronary vasospasm, but the
uthors of this study questioned if the release of
ndothelin-1 from normal coronary artery endothelial cells
as the primary cause or a consequence of 5-FU–related
ndothelial activation leading to cardiotoxicity (74,98).
Therefore, alternative mechanisms have been developed,
ncluding direct toxicity on myocardium, interaction with
oagulation system, and autoimmune responses (74,86).
ccumulation of 5-FU and its metabolites due to dihydro-
yrimidine deficiency may increase 5-FU–related cardiotox-
city, although the relationship between these 2 is unknown
84). Animal models have suggested an accumulation of
itrate in myocardial cells may be the causative mechanism
73,74,86). This accumulation is attributed to fluoroacetate
ormation, which interferes with the Krebs cycle. Fluoroac-
tate is generated from a degradation product of parenteral
-FU preparations, fluoroacetaldehyde (73,86). Animal
tudies have also shown the potential for 5-FU to induce
ose- and time-dependent depletion of high-energy phos-
hates in the ventricle (86,97). Lastly, apoptosis of myocar-
ial cells and endothelial cells may result in inflammatory
esions mimicking toxic myocarditis (84,86).
ACLITAXEL. Myocardial ischemia associated with paclitaxel
s thought to be multifactorial in etiology, with other drugs
nd underlying heart disease as possible contributing factors
90). In addition, the Cremophor EL vehicle in which
aclitaxel is formulated may be responsible for its cardiac ioxicity, and the mechanism is likely due to its induction of
istamine release (90).
EVACIZUMAB. The mechanism associated with bevacizumab-
nduced arterial thrombosis is unclear. It is thought, however,
hat VEGF may be involved. VEGF stimulates endothelial cell
roliferation, promotes endothelial cell survival, and helps
aintain vascular integrity (99). Therefore, anti-VEGF ther-
py may decrease the regenerative capability of endothelial cells
n response to trauma, leading to endothelial cell dysfunction
nd defects in the interior vascular lining exposing subendo-
helial collagen. As a result of subendothelial collagen exposure,
issue factor is activated increasing the risk for thrombotic
vents to occur (99,100). In addition, inhibiting VEGF causes
eduction in nitric oxide and prostacyclin, as well as increases
ematocrit and blood viscosity via overproduction of erythro-
oietin, all of which may predispose patients to an increased
isk of thromboembolic events (99).
iagnosis. The diagnosis of an ACS is based upon the
atient’s clinical presentation, ECG changes, and elevations
n cardiac enzymes. In 2007, the Joint Task Force of the
uropean Society of Cardiology, American College of
ardiology Foundation, the American Heart Association,
nd the World Health Federation redefined acute MI as a
erm that should be used when there is evidence of myo-
ardial necrosis in a clinical setting consistent with myocar-
ial ischemia (101).
reatment. Patients with suspected ACS should be man-
ged according to the guidelines established by American
ollege of Cardiology and American Heart Association
102,103). Cornerstones in ACS therapy include percuta-
eous coronary intervention, antiplatelet and anticoagulant
herapy, all of which may pose a problem in certain cancer
atients due to either thrombocytopenia or recent surgery.
urrently, there are no guidelines or prospective studies that
nclude such patients. However, in a retrospective study,
spirin use significantly improved 7-day survival in cancer
atients with thrombocytopenia and ACS without increas-
ng the bleeding risk (104). In addition, treatment with
eta-blockers also led to significantly improved 7-day sur-
ival in cancer patients with ACS (104).
-FU AND CAPECITABINE. 5-FU or capecitabine therapy
hould be discontinued in patients who develop chest pain.
n addition, antianginal therapy and a work-up for ischemia
hould be initiated. Based on the idea that coronary artery
pasm is involved in the mechanism of cardiac injury,
rophylactic treatment with coronary vasodilators (e.g.,
itrates and calcium-channel blockers) has been investi-
ated. However, the results of these studies have not shown
consistent benefit. Rechallenging patients with 5-FU or
apecitabine who previously had cardiotoxicity related to
hese agents remains controversial. A rechallenge with these
gents should be reserved only for patients having no
lternative therapeutic interventions and should be admin-
stered in a supervised environment. It may also be prudent
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apecitabine-induced cardiotoxicity (70,78,81,84).
ORAFENIB. According to the package insert, temporary or
ermanent discontinuation of sorafenib should be consid-
red in patients who develop cardiac ischemia.
EVACIZUMAB. Because studies excluded patients who had
ny history of stroke or MI within 12 months of enrollment,
he risks and benefits of bevacizumab treatment among
hese patients have not been established. Bevacizumab
herapy should be discontinued in patients who develop
evere ATEs during treatment. The safety of restarting of
evacizumab therapy after resolution of an ATE has not
een studied (10).
TN
TN and cancer often coexist in the same patient. In fact,
igh blood pressure is the most frequent comorbid condi-
ion reported in cancer registries (105). Additionally, epi-
emiological studies suggest the possibility that there is an
ssociation between the 2 and that HTN affects the overall
rognosis of cancer patients (106). New approaches to
ancer treatment disrupt angiogenesis; thereby patients re-
eiving these agents often will develop HTN (105). Table 3
ighlights the incidences of clinically significant HTN associ-
ted with selected anticancer agents.
ncidence. BEVACIZUMAB. HTN (any grade) is a common
dverse effect occurring in patients treated with bevaci-
umab, with an overall incidence of 4% to 35% reported in
linical trials (18,19,107–112). Grade 3 HTN occurred in
1% to 18% of patients (18,19,107,108). HTN developed at
ny time during therapy, and some data suggest there is a
ose relationship (108). Most patients who developed HTN
n clinical trials were adequately treated with antihyperten-
ives and continued bevacizumab therapy. However, wors-
ning HTN requiring hospitalization or discontinuation of
evacizumab therapy occurred in up to 1.7% of patients
10). Complications of bevacizumab-induced HTN have
ncluded hypertensive encephalopathy and central nervous
ystem hemorrhage (10).
ORAFENIB. HTN is a major adverse effect of sorafenib
herapy occurring in 17% to 43% of patients in clinical trials
96,113–116). Grade 3 or 4 HTN occurred in 1.4% to 38%
96,113–116). In a recent meta-analysis involving 4,599
hemotherapy Associated With Hypertension
Table 3 Chemotherapy Associated With Hypertension
Chemotherapy Agents Incidence
Frequency
of Use
Monoclonal antibody-based tyrosine kinase inhibitor
Bevacizumab (Avastin) (18,19,107–112) 4–35 
Small molecule tyrosine kinase inhibitors
Sorafenib (Nexavar) (96,113–116) 17–43 
Sunitinib (Sutent) (37,118–122) 5–47 t
or an explanation of the symbols, please see Table 1. Medication manufacturers and locations
s in Tables 1 and 2.atients treated with sorafenib therapy, the overall incidence
f HTN was 23.4%. Grade 3 or 4 HTN ranged from 2.1%
o 30.7% (117).
UNITINIB. In clinical trials, sunitinib was associated with
TN, with the incidence varying from 5% to 24%
118–122). Grade 3 HTN occurred in 2% to 8% (118–122).
n a retrospective review, sunitinib was found to have
ncreased blood pressure (150/100 mm Hg) in 47% of
atients, with grade 3 HTN seen in 17%. HTN occurred
ithin the first 4 weeks of therapy (37).
athophysiology. The mechanism of antiangiogenic
herapy-related HTN is not fully understood. However, it is
hought to be related to VEGF inhibition, which decreases
itric oxide production in the wall of the arterioles and other
esistance vessels (99). Nitric oxide is a natural vasodilator,
hereby blocking its production promotes vasoconstriction,
ncreased peripheral vascular resistance and blood pressure
99). Because bevacizumab decreases endothelial nitric ox-
de synthase activity, this may stimulate plasminogen acti-
ator inhibitor-1 expression, leading to an increased risk of
TN (123). It has also been hypothesized that VEGF may
ave effects on the renin-angiotensin system (124). How-
ver, Veronese et al. (125) demonstrated that serum cate-
holamine, renin, and aldosterone levels did not change
uring anti-VEGF therapy, lessening the likelihood that
he onset of HTN has an adrenergic or a renovascular
tiology. Finally it has been speculated that VEGF inhibi-
ion may be responsible for cholesterol emboli syndrome,
hich may account for bevacizumab-induced acute compli-
ations including HTN (126).
iagnosis. HTN is defined by JNC 7 (Seventh Report of
he Joint National Committee on Prevention, Detection,
valuation, and Treatment of High Blood Pressure) as
lood pressure 140/90 mm Hg. The JNC 7 classification
f blood pressure for adults is based on the average of 2 or
ore properly measured blood pressure readings on 2 or
ore visits. JNC 7 classifies individuals with HTN into
arious stages based on measured blood pressure values. When
valuating patients with HTN there are 3 objectives: 1) identify
he causes of HTN; 2) assess lifestyle and recognize cardiovas-
ular risk factors or comorbid conditions that may affect
rognosis or guide the choice of treatment; and 3) evaluate the
resence or absence of target organ damage associated with
TN (127).
reatment. The primary goal in the treatment of HTN is
o reduce morbidity and mortality and lower the risk of
ssociated target organ damage (e.g., cardiovascular and
erebrovascular events, renal failure). In treating HTN
nduced by antiangiogenic therapies, standard antihyperten-
ive medications should be initiated in concordance with
NC guidelines (127). HTN induced by bevacizumab,
orafenib, and sunitinib will most likely require more than 1
ntihypertensive medication, and close blood pressure mon-
toring is recommended. Discontinuation of antiangiogenic
herapy due to HTN is controversial since the appearance of
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igher treatment response (128).
When choosing an antihypertensive agent, there is evi-
ence that some antihypertensives may be more effective
han others, since the biological effect of these medications
n angiogenesis differs (117). In addition, it may be bene-
cial to use ACE inhibitors as first-line therapy due to their
bility to prevent proteinuria and plasminogen activator
nhibitor-1 expression (123). In vivo studies have also
hown that ACE inhibitors have the potential to reduce
icrocirculatory changes, decrease the catabolism of brady-
inin, and increase release of endothelial nitric oxide (109).
Drug–drug interactions should also be considered in
orafenib-treated patients. Sorafenib is metabolized via the
ytochrome p450 system, mainly by CYP3A4. Dihydropyr-
dine calcium-channel blockers (e.g., diltiazem and vera-
amil) should not be used in combination with sorafenib
ince they are both inhibitors of the CYP3A4 isoenzyme,
hereby substantially increasing sorafenib levels. If a
alcium-channel blocker is added, amlodipine and nifedi-
ine are preferred. The use of phosphodiesterase inhibitors
r nitrates to increase nitric oxide levels has been suggested
hen treating HTN associated with sorafenib therapy,
lthough further clinical studies are necessary (117). Finally,
ince HTN is a risk factor for the development of HF,
edications that have been shown to be beneficial in
reventing morbidity and mortality in HF patients (e.g.,
arvedilol, metoprolol succinate, ACE inhibitors, and an-
iotensin receptor blockers) may be considered as first-line
gents for treating HTN associated with antiangiogenic
herapy as well.
hromboembolism
ancer is known to produce a prothrombotic state. The risk
f thrombosis appears to be highest in cancer patients with
etastatic disease and in those with established risk factors.
isk factors include the use of central venous catheters and
hemotherapy Associatedith Venous Thromboembolism
Table 4 Chemotherapy AssociatedWith Venous Thromboembolism
Chemotherapy Agents Incidence (%)
Frequency
of Use
Alkylating agents
Cisplatin (Platinol-AQ) (130) 8.5 
Angiogenesis inhibitors
Lenalidomide (Revlimid) (144–149) 3–75* 
Thalidomide (Thalomid) (133–143) 1–58* 
Histone deacetylase inhibitor
Vorinostat (Zolinza) (10,131,132) 4.7–8 
Small molecule tyrosine kinase inhibitors
Erlotinib (Tarceva) (10) 3.9–11 
or an explanation of the  symbols, please see Table 1. *The incidence of venous thromboem-
olism varies widely in the literature for angiogenesis inhibitors depending on the patient’s disease
tatus, concomitant use of high- or low-dose dexamethasone, erythropoietin, or other chemother-
peutic agents, and whether or not thromboprophylaxis was employed during the study period.
edication manufacturers and locations: Platinol-AQ, Bristol-Myers Squibb, Princeton, New Jersey;c
evlimid and Thalomid, Celgene Corp., Summit, New Jersey; Zolinza, Merck & Co. Inc., Whitehouse
tation, New Jersey; Tarceva, OSI Pharmaceuticals Inc., Melville, New York.ssociated comorbidities such as immobility, HF, atrial
brillation, dehydration, and administration of concurrent
hemotherapy (129). Table 4 highlights the incidences of
linically significant venous thromboembolism (VTE) asso-
iated with selected chemotherapeutic agents.
ncidence. CISPLATIN. Platinum-based therapy has been
hown to increase the risk of thrombotic events in cancer
atients. In a retrospective review of 271 consecutive pa-
ients with urothelial transitional cell carcinoma receiving
isplatin-based chemotherapy, vascular events occurred in
5 patients (12.9%). When separating out the thromboem-
olic events in the 35 patients, 23 patients (8.5%) experi-
nced a deep vein thrombosis (DVT) or pulmonary embo-
ism (PE). Of these patients, 74% had events within the first
cycles of chemotherapy, and most patients had predispos-
ng risk factors such as large pelvic masses, coronary artery
isease, immobility, or a prior history of a thromboembolic
vent (130).
ORINOSTAT. The incidence of thromboembolism associ-
ted with vorinostat is 4.7% (10). This number is based on
he unpublished combined results of 2 clinical studies
valuating vorinostat in the treatment of 86 patients with
utaneous T-cell lymphoma (CTCL) (10). However, 2
rials have been published reporting the frequency of throm-
oembolism associated with vorinostat. A phase IIb trial
onducted in 74 CTCL patients found the incidence of
hromboembolic events was 5.4% (131). In addition, Duvic
t al. (132) established that PE and DVT occurred in 5%
nd 8% of patients, respectively.
HALIDOMIDE. Of the chemotherapeutic agents, thalido-
ide is most commonly associated with the development of
hromboembolic complications. Thalidomide monotherapy
s associated with low rates of thrombosis (5%) (133,134).
owever, this risk increases dramatically (3% to 58%) when
halidomide is used in newly diagnosed patients, as well as
hen used in combination with dexamethasone or chemo-
herapy, particularly doxorubicin, in the absence of throm-
oprophylaxis (133–143). Overall, the median time to onset
f a thrombotic event associated with thalidomide was
round 3 months (141).
ENALIDOMIDE. Lenalidomide is a thalidomide analog with
favorable toxicity profile that differs from the parent
olecule. However, it appears that the thrombotic risk is
till significant with lenalidomide. In clinical studies, the
ncidence of thromboembolism has varied widely among
eports, ranging anywhere from 3% to 75% (144–149). As a
ingle agent, lenalidomide does not significantly increase the
isk of VTE (141). However, the rate of thrombosis
uctuates considerably depending on the patients’ disease
tatus, concomitant use of high- or low-dose dexametha-
one, erythropoietin, or other chemotherapeutic agents, and
hether or not thromboprophylaxis was employed during
he study period (150). Risk factors associated with in-
reased rates of VTE include high doses of dexamethasone,
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Chemotherapy and Cardiotoxicity June 16, 2009:2231–47rythropoietin administration, and in 1 study, the rate was
ighest (75%) in newly diagnosed patients (141,150).
RLOTINIB. DVT has been reported in 3.9% of patients
eceiving erlotinib in combination with gemcitabine, com-
ared with 1.2% of patients who received gemcitabine
lone, for the treatment of pancreatic cancer. The overall
ncidence of grade 3 or 4 thrombotic events, including
VT, was 11% in the erlotinib group plus gemcitabine arm
nd 9% in the gemcitabine only arm (10). The manufacturer
btained these results from a trial conducted by Moore et al.
95); however, the incidence of thromboembolism was not
ublished.
athophysiology. Malignancy is associated with a baseline
ypercoagulable state due to many factors including release
f high levels of inflammatory cytokines with activation of
he clotting system and inhibition of natural anticoagulant
echanisms, particularly the activated protein C system,
mpaired fibrin polymerization and reduced fibrinolysis, and
lteration of endothelial surface (142). Due to the complex-
ty of this situation where multiple hemostatic abnormalities
xist, the mechanisms by which anticancer treatments con-
ribute to thrombosis remains to be clarified. Potential
actors that may contribute to chemotherapy-induced
hrombogenesis include the release of procoagulants and
ytokines by chemotherapy-induced tumor cell damage,
irect endothelial damage, as well as hepatotoxicity from
hemotherapeutic agents leading to decreased production of
ormally produced anticoagulants (130).
ISPLATIN. With cisplatin, there is some laboratory evi-
ence suggesting that it induces platelet activation and
ggregation, possibly through a mechanism involving
onocyte procoagulant activity. Cisplatin-based therapies
ay also alter endothelial cell integrity (130). Finally,
isplatin may elevate von Willebrand factor levels, cause
ypomagnesemia-induced vasospasm, and have antiangio-
enic activity (151,152).
HALIDOMIDE AND LENALIDOMIDE. It has been suggested
hat thalidomide-induced thromboembolism may involve
ts direct action on endothelial cells previously damaged by
oxorubicin (134). It also may involve an interaction be-
ween platelets and the endothelium (136,142). Increased
latelet aggregation and von Willebrand factor have been
ound in patients treated with thalidomide (136). Since
enalidomide is an analog of thalidomide, these same
echanisms may be responsible for its thrombosis.
iagnosis. The diagnostic test of choice for DVT is
ompression ultrasonography, due to its high sensitivity and
pecificity. When PE is suspected, spiral computed tomog-
aphy angiography is the diagnostic test of choice. Nuclear
edicine techniques (e.g., ventilation/perfusion scan) are
tilized less frequently. Magnetic resonance pulmonary
ngiography may be considered an alternative to computed
omography pulmonary angiography in patients who have
ontraindications to iodinated contrast media (141).
w
brevention of thromboembolism. THALIDOMIDE AND
ENALIDOMIDE. Due to the risk of thrombotic events,
everal preventative strategies have been investigated. There
ave been no randomized, prospective trials directly com-
aring different anticoagulants; therefore, there are no firm
uidelines on the management of these patients. However,
he International Myeloma Working Group recently pub-
ished recommendations regarding the prevention of
halidomide- and lenalidomide-associated thrombosis in
yeloma patients (141). In this review, the authors advise
ailoring the choice of thromboprophylaxis based on indi-
idual risk factors (e.g., age, obesity, previous VTE, central
enous catheter, immobility, comorbidities, concomitant
edications, surgery, inherited thrombophilia), as well as
yeloma-related risk factors (diagnosis and hyperviscosity)
nd myeloma therapy-related risk factors (concomitant
teroids, doxorubicin). The panel recommended no prophy-
axis in those patients receiving thalidomide or lenalidomide
s a single agent. Aspirin (81 to 325 mg) may be used in
atients with no risk factors or 1 risk factor for VTE.
ow-molecular-weight heparin (LMWH) equivalent to 40
g enoxaparin or full-dose warfarin is recommended for
hose with 2 or more individual/myeloma-related risk fac-
ors or those receiving concomitant high-dose dexametha-
one or doxorubicin (141). Ongoing randomized trials
omparing aspirin, warfarin, and LMWH will help to
efine an optimal prophylaxis strategy (141).
reatment of thromboembolism. Once a VTE is diag-
osed, the goal of treatment is to relieve symptoms and
revent embolization and recurrence. Patients who develop
TE should be treated in accordance to established guide-
ines put forth by the American College of Chest Physi-
ians. In general, for patients with VTE and cancer, the
uidelines recommend LMWH for the first 3 to 6 months
f long-term anticoagulant therapy, followed by anticoagu-
ant therapy with warfarin or LMWH indefinitely or until
he cancer is resolved (153).
HALIDOMIDE AND LENALIDOMIDE. LMWH (enoxaparin,
alteparin, or nadroparin) should be used as initial treat-
ent, with a transition to warfarin therapy targeting an
nternational normalized ratio of 2 to 3, if the risk on
oncurrent thrombocytopenia is low. The optimal duration
f therapy remains controversial; however, extended therapy
s recommended due to the high risk of recurrence (10%)
hemotherapy Associated With Bradycardia*
Table 5 Chemotherapy Associated With Bradycardia*
Chemotherapy Agents Incidence (%)
Frequency
of Use
Angiogenesis inhibitor
Thalidomide (Thalomid) (138,140,156–159) 0.12–55* 
Antimicrotubule agent
Paclitaxel (Taxol) (10,90,91,154,155) 0.1–31* 
or an explanation of the  symbols, please see Table 1. *The incidence of bradycardia varies
idely in the literature for these agents due to the differences in study design, definition of
radycardia, and numbers of patients. Medication manufacturers and locations as in Tables 2 and 4.
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June 16, 2009:2231–47 Chemotherapy and Cardiotoxicityn the year after discontinuation of anticoagulant therapy in
ancer patients who have had a VTE (141). It is also
ecommended that it is reasonable to briefly discontinue
halidomide or lenalidomide and resume therapy once full
nticoagulation has been established (141).
radycardia
radycardia and heart block may be caused by multiple
onditions in cancer patients. Fibrosis due to old age or
adiation therapy, in addition to conditions like amyloidosis
nd primary cardiac tumors, can affect the cardiac conduc-
ion system (129). Also, in patients with cancer, bradycardia
nd heart block have been associated with several chemo-
herapeutic agents, with the 2 most clinically significant
gents being paclitaxel and thalidomide. Table 5 highlights
he incidences of bradycardia associated with selected che-
otherapeutic agents.
ncidence. PACLITAXEL. Cardiac toxicity was first recog-
ized during continuous monitoring of patients receiving
aclitaxel treatment, which was performed due to the high
ncidence of serious hypersensitivity reactions noted during
arly phase I clinical trials. After cardiac events were noted,
atients with known cardiac disease or on any medication
hat may interfere with cardiac conduction were excluded
rom clinical trials (91). Paclitaxel has been shown to cause
ardiac arrhythmias, including an asymptomatic bradycardia
hat is reversible (90,154,155). The incidence of bradycardia
aused by paclitaxel varies in the literature from 0.1% to
1% (10,90,91,154,155).
HALIDOMIDE. The incidence of bradycardia associated
ith thalidomide is not reported in the package insert.
ost-marketing surveillance studies have reported an ad-
erse event reporting rate of 0.12% (156). Correspondingly,
n a phase III trial of thalidomide plus dexamethasone
ompared with dexamethasone alone in newly diagnosed
ultiple myeloma patients, sinus bradycardia in the thalid-
mide group was seen in only 2% of patients (137).
lthough these reports suggest that the incidence of brady-
ardia appears to be low, other studies have found the rate
f sinus bradycardia associated with thalidomide therapy to
e anywhere from 5% to 55% (138,140,157–159).
athophysiology. PACLITAXEL. It has been suggested that
aclitaxel may cause arrhythmias via its effects on the
urkinje system or extracardiac autonomic control (154). In
ddition, Cremophor EL, which is the vehicle that pacli-
axel is formulated in, may be responsible for its cardiac
isturbances. In cases of hypersensitivity reactions, Cremo-
hor EL is known to induce histamine release (90). Stim-
lation of the histamine receptors in the cardiac tissue can
ncrease myocardial oxygen demand as well as coronary
asoconstriction and chronotropic effects (91). In animal
tudies, stimulation of the H1 receptors has resulted in
rolongation of atrioventricular conduction, depression of
onduction in the Purkinje tissue, myocardial cell injury,
nd ventricular arrhythmias (91). Therefore, activation of sistamine receptors in cardiac tissue may be a plausible
xplanation for the cardiotoxicity reported with paclitaxel
91). Of note, paclitaxel is formulated with the highest
oncentration of Cremophor EL per dose of all agents in
linical use, and if Cremophor EL is the agent responsible
or the cardiac toxicity, the mechanism is likely due to its
nduction of histamine release (90).
HALIDOMIDE. The underlying mechanism of thalidomide-
nduced bradycardia remains unclear. It has been postulated,
owever, that the bradycardia may be due to central sedative
ffects or an activation of the vasovagal pathway. Thalido-
ide has been shown to reduce tumor necrosis factor-alpha
evels, and as a consequence, this causes rapid and complete
nhibition of the dorsal motor neurons (part of the nucleus
f the vagus nerve). This could lead to over-reactivity of the
arasympathetic nervous system resulting in bradycardia
nd exacerbate underlying conduction disturbances. In ad-
ition, it has also been proposed that thalidomide may
nduce hypothyroidism in some patients leading to brady-
ardia (158,160).
iagnosis. Bradycardia is typically defined as a heart rate
60 beats/min. Many patients are asymptomatic with a
eart rate lower than 50 beats/min; however, some
atients may have associated symptoms such as fatigue,
imitations in physically activity, syncope, or dizziness.
iagnostic tests to determine the type of bradycardia
nclude an electrocardiogram, Holter monitor, and
creening for underlying disorders such as thyroid disease
r electrolyte abnormalities.
reatment. PACLITAXEL. In general, bradycardia associated
ith paclitaxel use is without clinical significance; however,
ome patients have required pacemaker implantation. Ac-
ording to the package insert, frequent vital sign monitor-
ng, particularly during the first hour of paclitaxel infusion,
s recommended. Continuous cardiac monitoring is not
equired except for patients with serious conduction abnor-
alities (10). In addition, all patients should be given a
re-medication regimen before paclitaxel infusion to pre-
ent severe hypersensitivity reactions. Since histamine re-
ease has been implicated as a possible mechanism for
aclitaxel-induced bradycardia, this may also aid in the
revention of bradycardia as well. In any case, bradycardia
lone does not appear to be an indication to discontinue
aclitaxel treatment, since many of these cases are asymp-
omatic. However, if the patient develops bradycardia with
rogressive atrioventricular conduction disturbances and/or
linically significant hemodynamic effects, paclitaxel discon-
inuation is warranted.
HALIDOMIDE. Treatment of bradycardia depends on
hether the patient is symptomatic. If the patient is
symptomatic, no treatment is usually necessary, but careful
bservation is warranted. In some cases, a reduction in the
aily dosing of thalidomide may be required. For the
reatment of symptomatic bradycardia, thalidomide therapy
hould be discontinued. Furthermore, in patients with
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Chemotherapy and Cardiotoxicity June 16, 2009:2231–47ymptomatic third-degree atrioventricular block, a perma-
ent pacemaker is indicated. In multiple myeloma patients
ith disease responsive to thalidomide therapy where no
ther therapeutic alternatives are available, these patients
ave had pacemakers implanted to be able to continue
halidomide (160,161). In all cases, concomitant medication
nducing bradycardia such as beta-blockers, calcium-
hannel blockers, and digoxin should be avoided. In addi-
ion, a thyroid-stimulating hormone level should be ob-
ained in these patients to rule out hypothyroidism as a
ause of bradycardia.
T Prolongation
T interval prolongation is an abnormality of the electrical
ctivity of the heart that places individuals at risk for
entricular arrhythmias. Cancer patients may be particularly
rone to QT prolongation, since 16% to 36% of cancer
atients have been shown to have baseline ECG abnormal-
ties (129,162). In addition, cancer patients have a high
revalence of comorbid diseases, including structural heart
isease, renal and hepatic dysfunction, as well as use
oncomitant medications that are known to prolong the QT
nterval (e.g., antiemetics, antifungals, quinolone antibiot-
cs). Furthermore, cancer patients often experience nausea,
omiting, diarrhea, and decreased oral intake, which may
ead to electrolyte disturbances, placing the patient at risk
or QT prolongation (129,162). Table 6 highlights the
ncidences of QT prolongation associated with selected
hemotherapeutic agents.
ncidence. ARSENIC TRIOXIDE. The incidence of QT pro-
ongation ranges widely in the published literature largely
ue to the small number of patients in each of the clinical
rials. In the package insert, the U.S. Multicenter Study of
rsenic Trioxide is the only published data utilized to report
he incidence of QT prolongation (163). In this trial, over
60 ECG tracings from 40 patients with refractory or
elapsed acute promyelocytic leukemia treated with arsenic
ere evaluated for QT prolongation. Sixteen of 40 patients
40%) had at least 1 ECG tracing with a QTc interval500
hemotherapy Associated With QT Prolongation*
Table 6 Chemotherapy Associated With QT Prolongation*
Chemotherapy Agents Incidence (%)
Frequency
of Use
Histone deacetylase inhibitor
Vorinostat (Zolinza) (10,131) 3.5–6 
Miscellaneous
Arsenic trioxide (Trisenox) (10,163–170) 26–93* 
Small molecule tyrosine kinase inhibitors
Dasatinib (Sprycel) (10) 1–3 
Lapatinib (Tykerb) (10) 16 
Nilotinib (Tasigna) (171–173) 1–10 
or an explanation of the symbols, please see Table 1. *The incidence of QT prolongation varies
idely in the literature for arsenic due to the differences in study design, definition of QT
rolongation, and numbers of patients. Medication manufacturers and locations: Trisenox, Cepha-g
on Oncology, Frazer, Pennsylvania; Tasigna, Novartis Pharmaceuticals Corporation, East Hanover,
ew Jersey; others as in Tables 1 and 4.s. The QT interval was prolonged anywhere from 1 to 5
eeks after arsenic infusion, and then returned to baseline
y the end of 8 weeks after arsenic therapy (10,163).
owever, in other trials the incidence of QT prolongation
anges from 26% to 93% (164–170).
ASATINIB. In an FDA review of chronic myeloid leukemia
atients treated with dasatinib, 9 patients (1.8%) of the
afety population had at least 1 episode of QT prolongation
eported as an adverse event, and 7 additional patients
1.4%) were found to have QTc prolongation of 500 ms
n ECG. Furthermore, in a briefing document for Oncol-
gy Drug Advisory Committee, QT prolongation was
eported to occur in 2% to 3% of patients treated with
asatinib (FDA websites). Finally, the package insert states
hat 9 patients have had QTc prolongation reported as an
dverse event and that 3 patients (1%) experienced a QTC
nterval 500 ms (10).
APATINIB. The QT prolongation potential of lapatinib was
ssessed in an uncontrolled, open-label dose escalation study
n advanced cancer patients. Eighty-one patients received
aily doses of lapatinib ranging from 175 to 1,800 mg/day.
erial ECGs were collected to evaluate the effect of lapa-
inib on QT intervals. Thirteen (16%) of the 81 subjects
ere found to have either QTc 480 ms or an increase in
Tc 60 ms from baseline on ECG (10). To date, there is
o published information on this particular study.
ILOTINIB. According to the package insert, the incidence
f QT prolongation is 1% to 10%, and as part of the
pproval for nilotinib, the FDA has stipulated that nilotinib
arry a black box warning for QT prolongation. In a phase
study of 119 patients treated with nilotinib, the QT
nterval appeared to increase by 5 to 15 ms; however, an
xact incidence of QT prolongation was not reported in this
rial (171). Additionally, in a phase II open-label study, 3
1%) of 280 patients had QTc intervals 500 ms (172).
inally, in a phase II trial, increases of 60 ms were
bserved in 5 patients (4%) (173).
ORINOSTAT. The incidence of prolonged QT interval with
orinostat has been reported in 3.5% to 6% of patients (10).
definitive study of the effect of vorinostat on QTc has not
een conducted. However, in a total of 86 CTCL patients,
patients (3.5%) had QTc prolongation (10). In addition, a
etrospective analysis of 3 phase 1 and 2 phase 2 studies was
onducted by the manufacturer, and 5 (4.3%) of the 116
atients studied had QT prolongation (10). In 49 non-
TCL patients from 3 clinical trials who had complete
valuations of the QT interval, 3 (6%) patients experienced
T prolongation (10). Of the trials used to calculate the
ncidence of QT prolongation found in the package insert,
nly 1 of these trials is published. In a phase IIb trial
onducted in 74 patients with CTCL, QTc prolongation
as noted in 3 (4%) patients (131).
athophysiology. The mechanism underlying QT prolon-
ation associated with the medications mentioned in the
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June 16, 2009:2231–47 Chemotherapy and Cardiotoxicityreceding text remains unknown. When discussing drug-
nduced QT prolongation, it is now understood that the
lockade of delayed rectifier potassium current by medica-
ions is at least in part responsible for their pro-arrhythmic
ffect. In addition, 1 or more risk factors in the presence of
nderlying long QT syndrome may lead to significant QT
nterval prolongation (174).
iagnosis. QT prolongation is an electrocardiographic
iagnosis. The definition of QT prolongation varies in the
edical literature, and definitive values that place patients at
isk for ventricular complications have not been established.
uidelines for assessment of prolonged QTc values provide
linical direction in the assessment of patients at risk for
ardiac events. A QTc interval is considered normal if it is
440 ms and prolonged in men and women if it is longer
han 450 and 470 ms, respectively. Increases of 60 ms
rom baseline or 500 ms after administration of a medi-
ation raise concern about the potential risk of an arrhyth-
ia. Both congenital and acquired factors may be respon-
ible for QT interval prolongation. Some of the most
ommonly cited risk factors include female gender, elderly
ge, myocardial ischemia/infarction, HF, electrolyte imbal-
nces, bradycardia, and medications with QT-prolonging
ffects (174).
reatment. With each of the anticancer medications re-
iewed, the manufacturer has made recommendations for
aseline and periodic ECG monitoring, as well as dosage
djustments or discontinuation of therapy that may be
ecessary in the face of QT prolongation. In addition, all of
hese agents should be used cautiously in patients with risk
actors for developing QT prolongation (e.g., electrolyte
bnormalities, congenital long QT syndrome, concomitant
ntiarrhythmic medicines or other drugs known to cause
T prolongation, cumulative high-dose anthracycline ther-
py). In addition, hypokalemia and hypomagnesemia should
e corrected before initiating these medications (10). Fi-
ally, before treatment patients should be informed of the
isk of arrhythmias and to report any cardiac symptoms such
s palpitations.
The complications of QT interval prolongation, includ-
ng arrhythmias and torsade de pointes, are rare but can
ave life-threatening consequences. If a patient does de-
elop torsade de pointes, intravenous magnesium sulfate 2 g
s the initial therapy of choice regardless of serum magne-
ium level. Nonsynchronized defibrillation may be indicated
f sustained, hemodynamically unstable polymorphic ven-
ricular tachycardia or fibrillation develops. Overdrive trans-
enous pacing may be used to shorten the QTc. Pacing is
ighly effective in preventing recurrence and may be useful
n cases refractory to magnesium or when torsade de pointes
s precipitated by bradycardia. If overdrive pacing is initi-
ted, short-term pacing rates of 90 to 110 beats/min should
e used. Isoproterenol titrated to a heart rate90 beats/min
s another option in patients, and it is useful when tempo-
ary pacing is unavailable or while preparing for transvenous
atheter insertion. In addition, it is always imperative toaintain serum potassium levels in the high-normal range,
nd discontinue any QT prolonging medications and drugs
nterfering with patients’ metabolism (175).
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